These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23529583)

  • 41. Response of pediatric uveitis to tumor necrosis factor-α inhibitors.
    Lerman MA; Burnham JM; Chang PY; Daniel E; Foster CS; Hennessy S; Jabs DA; Joffe MM; Kaçmaz RO; Levy-Clarke GA; Mills MD; Nussenblatt RB; Rosenbaum JT; Suhler EB; Thorne JE; Kempen JH
    J Rheumatol; 2013 Aug; 40(8):1394-403. PubMed ID: 23818712
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recommendations for the use of methotrexate in juvenile idiopathic arthritis.
    Niehues T; Lankisch P
    Paediatr Drugs; 2006; 8(6):347-56. PubMed ID: 17154642
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapeutic effects of the anti-tumor necrosis factor monoclonal antibody, infliximab, in four children with refractory juvenile idiopathic arthritis.
    Norambuena R X; Mallol J; Ríos M G; Quevedo R F; Quezada L A
    Allergol Immunopathol (Madr); 2007; 35(2):52-6. PubMed ID: 17428400
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis.
    Angeles-Han ST; Ringold S; Beukelman T; Lovell D; Cuello CA; Becker ML; Colbert RA; Feldman BM; Holland GN; Ferguson PJ; Gewanter H; Guzman J; Horonjeff J; Nigrovic PA; Ombrello MJ; Passo MH; Stoll ML; Rabinovich CE; Sen HN; Schneider R; Halyabar O; Hays K; Shah AA; Sullivan N; Szymanski AM; Turgunbaev M; Turner A; Reston J
    Arthritis Care Res (Hoboken); 2019 Jun; 71(6):703-716. PubMed ID: 31021540
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pediatric rheumatology: JIA, treatment and possible risk of malignancies.
    Ruperto N; Martini A
    Nat Rev Rheumatol; 2011 Jan; 7(1):6-7. PubMed ID: 21135880
    [No Abstract]   [Full Text] [Related]  

  • 46. Initiation of rheumatoid arthritis treatments and the risk of serious infections.
    Grijalva CG; Kaltenbach L; Arbogast PG; Mitchel EF; Griffin MR
    Rheumatology (Oxford); 2010 Jan; 49(1):82-90. PubMed ID: 19906833
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
    Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serious musculoskeletal infections in children receiving anti-tumor necrosis factor-alpha therapy: a case series.
    Morishita K; Petty R; Cairns R; Bolaria R; Cabral D; Turvey S
    Clin Rheumatol; 2010 Jun; 29(6):677-81. PubMed ID: 20383549
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recent advances in the use of Anti-TNFα therapy for the treatment of juvenile idiopathic arthritis.
    Taddio A; Cattalini M; Simonini G; Cimaz R
    Expert Rev Clin Immunol; 2016 Jun; 12(6):641-9. PubMed ID: 26809126
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Juvenile idiopathic arthritis-associated uveitis.
    Clarke SL; Sen ES; Ramanan AV
    Pediatr Rheumatol Online J; 2016 Apr; 14(1):27. PubMed ID: 27121190
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of the COVID-19 Pandemic on the Management of Juvenile Idiopathic Arthritis: Analysis of United States Commercial Insurance Data.
    Horton DB; Yang Y; Neikirk A; Huang C; Crystal S; Davidow A; Haynes K; Gerhard T; Rose CD; Strom BL; Parlett L
    J Clin Rheumatol; 2023 Dec; 29(8):388-395. PubMed ID: 37798830
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effects of TNF-alpha inhibitor therapy on the incidence of infection in JIA children: a meta-analysis.
    Nagy A; Mátrai P; Hegyi P; Alizadeh H; Bajor J; Czopf L; Gyöngyi Z; Kiss Z; Márta K; Simon M; Szilágyi ÁL; Veres G; Mosdósi B
    Pediatr Rheumatol Online J; 2019 Jan; 17(1):4. PubMed ID: 30658717
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry.
    Beukelman T; Ringold S; Davis TE; DeWitt EM; Pelajo CF; Weiss PF; Kimura Y;
    J Rheumatol; 2012 Sep; 39(9):1867-74. PubMed ID: 22859354
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.
    Ramanan AV; Dick AD; Jones AP; Hughes DA; McKay A; Rosala-Hallas A; Williamson PR; Hardwick B; Hickey H; Rainford N; Hickey G; Kolamunnage-Dona R; Culeddu G; Plumpton C; Wood E; Compeyrot-Lacassagne S; Woo P; Edelsten C; Beresford MW
    Health Technol Assess; 2019 Apr; 23(15):1-140. PubMed ID: 31033434
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis.
    Tynjälä P; Lahdenne P; Vähäsalo P; Kautiainen H; Honkanen V
    Ann Rheum Dis; 2006 Aug; 65(8):1044-9. PubMed ID: 16449314
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Update on biologic therapies for juvenile idiopathic arthritis-associated uveitis.
    Thomas J; Kuthyar S; Shantha JG; Angeles-Han ST; Yeh S
    Ann Eye Sci; 2021 Jun; 6():. PubMed ID: 34131629
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting.
    Tarkiainen M; Tynjälä P; Vähäsalo P; Lahdenne P
    Rheumatology (Oxford); 2015 Jul; 54(7):1170-6. PubMed ID: 25504896
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Methotrexate for treating juvenile idiopathic arthritis.
    Takken T; Van der Net J; Helders PJ
    Cochrane Database Syst Rev; 2001; 2001(3):CD003129. PubMed ID: 11687037
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Methotrexate for treating juvenile idiopathic arthritis.
    Takken T; Van Der Net J; Helders PJ
    Cochrane Database Syst Rev; 2001; (4):CD003129. PubMed ID: 11687174
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis.
    Tappeiner C; Mesquida M; Adán A; Anton J; Ramanan AV; Carreno E; Mackensen F; Kotaniemi K; de Boer JH; Bou R; de Vicuña CG; Heiligenhaus A
    J Rheumatol; 2016 Dec; 43(12):2183-2188. PubMed ID: 27633821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.